RESUMO
We introduce the notion of N = 1 abstract super loop equations and provide two equivalent ways of solving them. The first approach is a recursive formalism that can be thought of as a supersymmetric generalization of the Eynard-Orantin topological recursion, based on the geometry of a local super spectral curve. The second approach is based on the framework of super Airy structures. The resulting recursive formalism can be applied to compute correlation functions for a variety of examples related to 2d supergravity.
RESUMO
We introduce super quantum Airy structures, which provide a supersymmetric generalization of quantum Airy structures. We prove that to a given super quantum Airy structure one can assign a unique set of free energies, which satisfy a supersymmetric generalization of the topological recursion. We reveal and discuss various properties of these supersymmetric structures, in particular their gauge transformations, classical limit, peculiar role of fermionic variables, and graphical representation of recursion relations. Furthermore, we present various examples of super quantum Airy structures, both finite-dimensional-which include well known superalgebras and super Frobenius algebras, and whose classification scheme we also discuss-as well as infinite-dimensional, that arise in the realm of vertex operator super algebras.
RESUMO
Bone marrow stem cell therapy has emerged as a promising approach to improve healing of the infarcted myocardium. Despite initial excitement, recent clinical trials using non-homogenous stem cells preparations showed variable and mixed results. Selected CD133(+) hematopoietic stem cells are candidate cells with high potential. Herein, we report the one-year safety analysis on the initial 20 patients enrolled in the COMPARE-AMI trial, the first double-blind randomized controlled trial comparing the safety, efficacy, and functional effect of intracoronary injection of selected CD133(+) cells to placebo following acute myocardial infarction with persistent left ventricular dysfunction. At one year, there is no protocol-related complication to report such as death, myocardial infarction, stroke, or sustained ventricular arrhythmia. In addition, the left ventricular ejection fraction significantly improved at four months as compared to baseline and remained significantly higher at one year. These data indicate that in the setting of the COMPARE-AMI trial, the intracoronary injection of selected CD133(+) stem cells is secure and feasible in patients with left ventricle dysfunction following acute myocardial infarction.
RESUMO
Stem cell therapy has emerged as a promising approach to improve healing of the infarcted myocardium, to treat or prevent cardiac failure, and to restore lost cardiac function. Despite initial excitement, recent clinical trials using nonhomogenous human stem cells preparations showed variable results, raising concerns about the best cell type to transplant. Selected CD133(+) hematopoietic stem cells are promising candidate cells with great potential. COMPARE-acute myocardial infarction (AMI) study is a phase II, randomized, double-blind, placebo-controlled trial evaluating the safety and effectiveness of intracoronary CD133(+)-enriched hematopoietic bone marrow stem cells in patients with acute myocardial infarction and persistent left ventricular dysfunction. Patients who underwent successful percutaneous coronary intervention and present a persistent left ventricular ejection fraction <50% will be eligible to have bone marrow aspiration and randomized for intracoronary injection of selected CD 133(+) bone marrow cells vs placebo. The primary end point is a composite of a safety and efficacy end points evaluating the change at 4 months in the coronary atherosclerotic burden progression proximal and distal to the coronary stent in the infarct related artery; and the change in global left ventricular ejection fraction at 4 months relative to baseline as measured by magnetic resonance imaging. The secondary end point will be the occurrence of a major adverse cardiac event. To date, 14 patients were successfully randomized and treated without any protocol-related complication. COMPARE-AMI trial will help identify the effect of a selected population of the bone marrow stem cells on cardiac recovery of infarcted myocardium.
